Podcasts

Episode 1 |Improving Survival In Oncogene Driven Lung Cancer

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Improving Survival In Oncogene Driven Lung Cancer

Episode Summary

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Prof Ben Solomon & A/Prof Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.

Show Hosts

This episode’s host are:

  • Prof Ben Solomon, Scientific Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer
  • A/Prof Thomas John, Scientific Committee Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer Centre

Play Episode 1 |Improving Survival In Oncogene Driven Lung Cancer

More Podcasts

In this Podcast, Mark Scott talks with Alexandra Golledge about her challenges in diagnosis, searching for the best treatments available, living in a regional area
Prof Nick Pavlakis and Prof Emily Stone join discuss the remarkable advances in screening, diagnosing and treating lung cancer that occurred during 2020.
Dorothy Keefe, CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients.
A fireside chat with Prunella Blinman, Shankar Siva and our three Preceptees: Anna Lawless, Abhijit Pal and Melanie Rabbets about their experiences, their learnings, what
In this episode, Prof Anna Nowak and A/Prof Steven Kao discuss the emerging treatments for mesothelioma patients and the DREAM3R trial.
In this episode, Prof Emily Stone and Prof Kwun Fong, both long time advocates and researchers in early screening discuss the challenges of implementing a